- Business Wire•6 days ago
Provectus Biopharmaceuticals, Inc. , a clinical-stage oncology and dermatology biopharmaceutical company , today announced receipt of notification from the NYSE MKT LLC that the Company is not in compliance with certain NYSE MKT continued listing standards relating to stockholders' equity.
- Business Wire•22 days agoProvectus Biopharmaceuticals Announces Poster Presentation on PV-10 at Society for Immunotherapy of Cancer 2016 Annual Meeting
Provectus Biopharmaceuticals, Inc. , a clinical-stage oncology and dermatology biopharmaceutical company , today announced the presentation of data on PV-10 at the Society for Immunotherapy of Cancer 2016 Annual Meeting.
- Associated Press•26 days ago
On a per-share basis, the Knoxville, Tennessee-based company said it had a loss of 4 cents. In the final minutes of trading on Thursday, the company's shares hit 5 cents. A year ago, they were trading ...
PVCT : Summary for Provectus Biopharmaceuticals, I - Yahoo Finance
Provectus Biopharmaceuticals, Inc. (PVCT)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.01 - 0.02|
|52 Week Range||0.01 - 0.54|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.09|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|